DFCM
SYRE icon

Dark Forest Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Dark Forest Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$461K Buy
+5,192
New +$379K 0.03% 666
2025
Q4 		– Sell
-14,733
Closed -$247K – 1333
2025
Q3 		$247K Buy
+14,733
New +$240K 0.01% 1059

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Dark Forest Capital Management's SYRE Position: Q2 2026 in Review

Dark Forest Capital Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 5,192 shares worth $461K. The stake represents 0.03% of the portfolio and ranks #666 among its holdings. This is a return to the name: Dark Forest Capital Management previously reported a position in SYRE as recently as Q3 2025.

Dark Forest Capital Management first reported a position in SYRE in Q3 2025 and has held it in 2 quarters since. 267 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Dark Forest Capital Management held 5,192 shares of Spyre Therapeutics worth $461K as of Q2 2026.
  • Spyre Therapeutics was a new Dark Forest Capital Management position in Q2 2026.
  • Spyre Therapeutics made up 0.03% of Dark Forest Capital Management's portfolio in Q2 2026, its #666 holding.
  • Dark Forest Capital Management first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 267 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Dark Forest Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.